Mary's Prime Time Issue 1

Coverage and Commentary on the Top Cannabis Conferences
Welcome to the first issue of Mary’s Prime Time!
This is the first issue of Mary’s Prime Time, an occasional publication that will report on presentations from cannabis conferences around the
globe. The goal is as simple as it is complex: to provide the public with the latest research on, and discussion of, cannabis as medicine.
In the past decade there has been an explosion of interest in medical cannabis. A constant stream of ballot initiatives and state legislation in
the U.S. has opened the door for patients to legally acquire this medicine that is still prohibited by the U.S. federal government. Around the
globe there is even more change as entire countries legalize medical access.
Concurrent with reform is an extraordinarily dynamic expansion of research with results being presented at dozens of conferences around the
globe. At Mary’s Medicinals we realized that this valuable information was being shared with the few hundred individuals lucky enough to
be in attendance but little was being done to disseminate it to the thousands who want to know more about the medicinal properties of this
wondrous plant.
We now know that cannabis has been a companion of mankind for tens of thousands of years. But it was not until the early 1990s that
we learned just how cannabis provides the therapeutic action for so many different diseases when the ECS was
discovered. The ECS—endocannabinoid system—creates cannabinoid like substances which help us maintain our
homeostasis (physiological balance).
This discovery ignited a new age of cannabis research. Scientists and pharmaceutical companies were quick to
see the promise of a substance that targets the regulation of a major physiological system. While U.S. researchers
continue to struggle under the shackles of an outmoded federal prohibition, researchers in Europe, Israel, and South
America have been energetically exploring the wonders of cannabis. The results are promising and often remarkable.
Without question, discovery of the ECS began this exciting new age of cannabis-focused scientific discoveries and
research. Mary’s Prime Time will bring that science to those who need it most -- patients, healthcare providers and
caregivers.
Conference Facts
Alice O’Leary Randall
Editor-in-Chief, Mary’s Prime Time
Title: NUNM Medical Cannabis Conference
Sponsor: National University of Natural Medicine (NUNM)
Dates: July 29-30, 2017
Venue: NUNM Campus, Portland, Oregon
Attendees: 50 in person, about 60 online
Presenters: Eleven total. This publication reports on six presenters.
Meeting Background: This is the third year of the NUNM Medical Cannabis Conference. Recordings of the
conferences (2017 and previous years) are available at the NUNM website. Link: nunm.edu/ceonline
Miscellaneous:
• Currently, 19 states, the District of Columbia, and the US territories of Puerto Rico and the US Virgin Islands all
have laws regulating naturopathic doctors (NDs). In these states and provinces, naturopathic doctors are required
to graduate from a four-year, residential naturopathic medical school and pass an extensive postdoctoral board
examination (NPLEX) in order to receive a license or registration.
• There are seven (7) accredited naturopathic programs in North America including two in Canada.
• MD vs. ND: “ .. the main difference between MD, DO, and ND medical programs is not the content of the
coursework, but rather the underlying philosophy which guides the physician to choose one treatment over
another.” Link: http://bit.ly/2BdYz85
1

What is Naturopathy?
The concept of naturopathy – the use of natural substances to promote
healing and well being – is probably as old as mankind but according
to Wikipedia, the term “naturopathy” wasn’t coined until 1895 and
was first used extensively by Benedict Lust, a German who brought the
concept to the U.S. in the early 1900s. The practice became somewhat
controversial in the mid-1900s as Western pharmaceuticals reached
a zenith in terms of development and promotion, crowding out “the
old ways.” By the end of the 20th century, however, consumers (i.e.,
patients) were revisiting naturopathic medicine and the practice saw a
resurgence of interest that continues today.
There are seventeen states that recognize naturopathy and numerous
schools that teach naturopathic physicians. This includes the
National University of Naturopathic Medicine (NUMN) in Portland,
Oregon. In late July, NUNM presented its third “Medical Cannabis
Conference” sponsored by the continuing education department at
NUNM.
What follows are reports on six of the eleven presentations at the
conference. All reports on the NUNM conference are written by
Mary’s Prime Time editor-in-chief, Alice O’Leary Randall. Those
interested in reviewing the proceedings can access the tapes via www.
nunm.edu/ce.
According to the American Association of Naturopathic Physicians:
“Naturopathic medicine is a distinct primary health care
profession, emphasizing prevention, treatment, and optimal
health through the use of therapeutic methods and substances that
encourage individuals’ inherent self-healing process. The practice
of naturopathic medicine includes modern and traditional,
scientific, and empirical methods.”
The merging of naturopaths and medical cannabis seems, well, a
natural fit. Cannabis is often described as an herb and naturopaths use
many herbs in their regimens. But the decades of false information
and the ongoing U.S. federal prohibition of cannabis had the same
chilling effect on many naturopaths as it has on medical professionals.
Some naturopaths have embraced cannabis, especially its component
cannabidiol (CBD). But other naturopathic doctors (NDs) still
shy away from the substance with worries of addiction and, more
realistically, concerns that the therapeutic abilities of cannabis may be
overblown and lead patients down the wrong pathway, especially in
the treatment of major illnesses such as cancer.
Mary’s Prime Time
Published peridiocally by
Mary’s Medicinals
Editor-in-Chief: Alice O’Leary Randall
alice@marysmedicinals.com
Special Assistant: Jesica Clark
Design: Luminary Digital
Published by Mary’s Medicinals, Denver, CO
Copyright (c) 2017 - All rights reserved
MarysMedicinals.com
This publication is solely for educational purposes and is not
intended to substitute for the medical advice of a treating physician.
Medicine and cannabis research is an ever-changing science.
Therefore, the editor, contributors and publisher do not accept
responsibility in the event of negative consequences incurred as a
result of the information presented in Mary’s Prime Time. We do not
claim this information is necessarily accurate by rigid scientific and
regulatory standards applied for medical treatment. No warranty,
expressed or implied, is furnished with respect to the material
contained in this publication. Readers are encouraged to consult
with personal physicians with respect to treatment of any medical
condition.
Cannabis in the Therapeutic Order
Presenter: Paul Bergner, ND
Director, North American Institute of
Medical Herbalism
The goal in attending the NUNM Conference was to learn how (or
if) naturopathic doctors are integrating medical cannabis into their
practice. With eleven speakers on the agenda (six are featured in
this issue of Mary’s Prime Time) it seemed a relatively wide range of
viewpoints would be presented but the first speaker made this writer’s
heart sink.
Paul Bergner is director of the North American Institute of Medical
Herbalism and editor of the Medical Herbalism Journal. A search of
the web after the conference revealed that Dr. Bergner has frequently
spoken on the adverse effects of cannabis and even though he issued
an opening disclaimer that he was speaking neither “for nor against”
medical cannabis his presentation had a distinct lean towards the
latter.
He began by explaining the Therapeutic Order, a concept that is not
necessarily new but has been re-packaged for the modern era by Drs.
Jared Zeff and Pamela Snider.
The Therapeutic Order emphasizes the classical regimen of the
ancients with focus on diet, exercise, rest, and emotions. Under
this scenario, herbal treatments are rather high on the chart. As Dr.
2

how Dr, Bergner treats cannabis dependent patients at his clinic. He
stated it was important to understand heavy cannabis users, which
he loosely described as using “multiple times a day,” as they become
“dependent” on the drug. He also stated that he believes “medical
cannabis users become heavy users.”
Bergner noted, the ancient Chinese felt that “once you resort to
needles and herbs you have already failed.”
But, as Dr. Bergner acknowledged, most naturopathic practitioners are
likely to use herbal remedies more readily than the Therapeutic Order
would dictate. So the question in this writer’s mind was, “Why not
cannabis?”
According to Dr. Bergner the reason lies in the concentrated forms and
high doses of cannabis that are needed. Besides, noted the herbalist, it
is not curative for any condition.
Micro-dosing cannabis apparently has not yet reached the proponents
of Therapeutic Order nor did the effective treatment of symptoms get
much respect from the opening speaker.
Dr. Bergner’s “long term strategies” for medical cannabis use are as
follows:
• Cannabis used for harm reduction.
• Cannabis used in place of, or to wean the patient off a more
dangerous drug, or to reduce its dose.
• Cannabis used to palliate while more substantial cure is put in
place.
My heart sank a little lower. While Bergner acknowledged that: 1)
cannabis is far safer than most pharmaceutical medications, 2) may
be good for those with terminal illness, 3) may help reduce the dose
of opioids, and 4) has no lethal dose (“Let’s have a parade,” he rather
cynically exclaimed), the speaker did nothing to elaborate on these
possibilities. Instead the presentation took a strong right turn towards
“Cannabis Adverse Effects” and for the next forty minutes we learned
His final ten slides did deal directly with therapeutic cannabis use but
even here the bias was obvious as he featured studies that, for the most
part, used the synthetic dronabinol (Marinol), not cannabis.
Dr. Bergner’s full presentation was two hours long and at the
conclusion this writer made a notation, “Focus of talk really treatment
of withdrawal.” While I had no idea what I would find at the
naturopathic conference I expected more tolerance and curiosity.
Only two hours into a two-day conference and I was feeling as if I had
wasted my time and was about to hear the naturopathic version of
“Just Say No.”
Practical Uses of Cannabinoids in Clinical Practice
Presenters: Chris D. Meletis, ND and Brian Martin, BSc, ND,
EmerChanges Health and Happiness Clinic
After such a dismal opening the next speaker, Chris Meletis, proved to
be a bracing gust of fresh air. He immediately distanced himself from
the first speaker saying, “Whereas Paul Bergner was speaking about
the marijuana side of cannabis sativa I am speaking about the hemp
side” and then proceeded to give a robust discussion of the cannabis
component cannabidiol (CBD).
He quickly ran through some informative slides providing information
on the hemp industry and the “self-medicating” population of the
U.S.A. His point was clear: Americans are self-medicating already with
hemp and all manner of other medications. Should naturopaths be
helping them do so effectively?
Dr. Meleits did not come to coddle or hold hands. He expected a
certain level of knowledge from the audience relative to CBD and the
endogenous cannabinoid system (ECS) as well as a proper perception
of the culture today which is, in Dr. Meletis’ view, suffering from a
wide array of inflammatory diseases including depression which he
feels is inflammation of the brain. CBD, he notes, is an excellent
anti-inflammatory agent and there is “plenty of research” to back up
this statement.
Meletis feels that CBD is safe and should be used as a preventative.
“Do you wait until a patient has it?” he asked the audience about an
dementia patient, “Or do you start preventatively?” For Dr. Meletis
the answer was obvious. He acknowledged that cannabinoid science
3

is in its infancy but feels that it has a bright future.
The former Dean of Naturopathic Medicine and Chief Medical
Officer at the NUNM, Meletis feels that hemp derived CBD is a
good option for starting patients on cannabinoid medicine because
it lacks the psychoactive effect (the “high”) of regular cannabis. Can
people get “high” on CBD? Meletis acknowledges that some patients
claim to get high from CBD so he asks them to explain why they feel
they are “high.” Meletis will tell them, “that’s not high, that’s alive.”
The patients, he says, “didn’t know how broken they were” until after
the CBD starts to work and their resulting sense of well-being is
sometimes euphoric.
Martin is clearly fascinated by CBD and stated “there is a huge
amount of interplay” between the body and CBD. An area of
particular interest for him is the role of CBD in controlling cortisol,
a naturally produced steroid hormone. As the body faces stress it will
produce increased amounts of cortisol which, in turn, can increase
blood sugar, suppress the immune system as well as numerous other
effects on the metabolism of humans. Using CBD to control cortisol
results in a win-win situation for the patient.
Meletis was keen on distinguishing between cannabis and hemp, or
as his final slide noted “hemp is not marijuana.” This proved to be a
common theme as the conference moved on through the weekend.
The next speaker was Brian Martin, a naturopathic doctor from
Canada. He continued the cannabidiol enthusiasm of Dr. Meletis
but noted that CBD is not as readily available in Canada as it is in the
U.S. This seemed a particularly odd statement given Canada’s liberal
national stance with respect to medical cannabis.
Unfortunately Martin was too rushed by time constraints to cover all
of the topics that are contained in his slides. His presentation, and
all the presenters, were taped by NUNM and those presentations are
available online.
Dr. Martin feels that CBD has a special place in the treatment
of alcoholism. In a fascinating 2013 study published in Elsevier’s
Pharmacology Biochemistry and Behavior (http://bit.ly/2AvoGvb) it
was discovered that transdermal delivery of CBD lessened alcoholinduced
neurodegeneration in rodents by almost 50%. It is obviously
preliminary research but it demonstrates the potential value of CBD in
medical treatment.
Hand-in-hand with neurodegeneration in alcoholism is the damage
that alcohol causes to the liver. Martin presented excerpts from a
2016 article that appeared in Clinical Liver Disease: A Multimedia
Review Journal entitled “Cannabinoids in liver diseases” (http://
bit.ly/2i9AKKO) that contained some conflicting but nevertheless
promising conclusions. And a study from 2017 demonstrated that
CBD is almost as effective as interferon in treating hepatitis C.
Dr. Martin concluded that “CBD is almost to good to be true.” He
paused for a moment before adding, “if it was a drug I wouldn’t
believe it.”
The CBD Evidence Base & Understanding Terpenes
Presenter: Kevin Spelman, PhD, CEO at Health Education and Research
University of Exeter/University of North Carolina
Kevin Spelman is a very entertaining speaker and that is probably why
he was asked to give two presentations at the NUNM conference. On
the first day Dr. Spelman spoke on “The CBD Evidence Base” and
on the second he discussed “Cannabis Chemistry: Understanding
Terpenes.” Not surprisingly there was some repetition but the purpose
of these conferences is to educate and repetition is a remarkably
effective educational tool. Additionally the two topics do blend nicely
and so both talks will be covered in this report.
Spelman unabashedly loves CBD but also feels that the current
climate is a bit “over zealous” with respect to CBD in general because
“people want to cash in.” He insists, however, that does not negate “the
remarkable science” that is emerging with respect cannabis and CBD
in particular.
He began by dispelling some popular misinformation about CBD
in particular the notion that CBD is non-psychotropic. CBD, says
Spelman, is not “euphoric” but it is “psychotropic.”
4

then re-infused, although there is some controversy about this process
and whether it destroys the desired chemical activity. Terpenes give
cannabis its distinctive odor. They do the same for pine trees, oranges,
lemons and on and on. But the emerging science is showing that
terpenes may influence the properties of cannabis in far more ways
than the aroma. Those who embrace the concept of the entourage
effect nod knowingly at this thought and say, “of course.”
The terpene talk was highly technical and made the audience
keenly aware of the complexities in the emerging field of medical
cannabinoids. Dr. Spelman noted that research is showing terpenes
and cannabinoids can effect even the tiniest of metabolic factors, SNPs
(pronounced “Snips” — Single Nucleotide Polymorphisms) which are
found in your DNA. One questioner at the end of the session pleaded
with Dr. Spelman, “I need you to write a book!,” she said to laughter,
“Because I can know some of these things but this is a lot! This is a
whole specialization and I’m looking at general patients.”
He also addressed the notion that CBD, when ingested, becomes
THC due to the interaction with stomach acid. While it may be
possible to do this in a test tube, Spelman says, in vivo the idea just
makes “no sense” and cited an article by Grotenhemen and Russo that
“lays to rest” this notion of molecular changes (see page 8).
Dr. Spelman did provide an excellent overview of using CBD in about
a half dozen conditions including inflammation, traumatic brain
injury (TBI), epilepsy, memory, and chronic pain, noting that nearly
all these conditions involve some form of inflammation and hence the
value of CBD. The current problem, one noted by several speakers
and questions from the audience, is dosing Spelman encouraged
using CBD in “nudges.” “It’s all about dose,” he said and noted that
effective doses can be as low as 0.01mg to 20 mg.
Terpenes
Spelman’s second presentation at the conference focused on terpenes
which have taken on a nearly mystical fascination in recent years.
Terpenes are any of a large group of volatile unsaturated hydrocarbons
found in the essential oils of plants, especially conifers, citrus trees
and cannabis.
Cannabis has many different terpenes and the science is so
sophisticated at this point that plants can be bred to possess certain
terpenes. They can be removed from plants prior to processing and
Spelman’s light hearted demeanor became very serious. And rightly
so. This is a question that burdens naturopaths, physicians and nurses
throughout the world. Spelman noted that cannabis is, after all, only
a plant and that naturopaths already use other plants on which there
there is far less data adding that at present “we are over-focused on
cannabis.” He counseled the audience member to begin learning the
cannabis plant just as she has learned about others and recognize that
this is simply a part of being a naturopath--it is a lifetime of learning
about plants. Spelman took one the mantras of cannabis opponents —
“cannabis is a gateway drug” — and put a new twist on it. “Cannabis,”
he said, “is a gateway plant for physicians to start taking medicinal
plants seriously.” Cannabis, Spelman believes, has made medical
doctors sit up and take notice of medicinal plants and, in Spelman’s
estimation, this is a tremendous opportunity for naturopathy and
Western medicine to come closer together.
Cannabinoids for Inflammation and the Immune System
Presenter: Sunil Pai, MD, House of Sanjevani Integrative Medicine Clinic
Unlike the other presenters, Sunil Pai is an M.D., not an N.D. but his philosophy of treatment seems
very in tune with the naturopaths. He is the author of An Inflammation Nation which examines the
prevention and treatment of disease through diet, lifestyle and the use of natural anti-inflammatories.
For Dr. Pai, cannabis, and in particular CBD, is a tailor-made agent for treatment of many inflammatory
disorders.
The operative statement is “tailor-made.” Numerous speakers at the NUNM Conference addressed
the idea of tailoring cannabis to the patient but Dr. Pai is practicing what he preaches at his clinic
in New Mexico. Not surprisingly given the title of his book, he also emphasized the need to treat
inflammation which in medical parlance is an “-itis” as in arthritis, gastritis, rhinitis, etc. There are
over 200 different forms of “itis” in medical books and conventional Western philosophy is to treat the
symptoms as opposed to the cause. Dr. Pai feels that careful treatment of the ECS is one way to actually
resolve inflammation problems and believes “ECS regulation is strongly influenced by the individual’s
microbiome.”
5

He emphasizes the need to treat “the moment” as well as the fact that it is “not as simple as on/off” when it comes to CB1 and CB2 receptors.
Indeed, several speakers at the conference emphasized this latter point: that treating disease via the ECS system is not simply a matter of
prescribing CBD and seeing the patient six months later. One of Dr. Pai’s slides put it well although not succinctly:
This system is not a simple on/off receptor effect. [It is a] complex response mechanism … between the endogenous and exogenous [molecules],
in cross-reactions with non-cannabinoid receptors, and in the plasticity of response, which is dependent on local tissue characteristics (state
of health) or the presence of other molecules.
“The most important thing of my lecture,” Dr. Pai said, “is that CB2 receptors act differently based on the state of pathology.” In fact, according
to Dr. Pai, CB2 receptors are more active in diseased organs. Thus, again, the need for tailoring the treatment on a regular basis when treating
the diseased state as well as microdosing. Too many clinicians err in thinking that a patient who responds well initially to CBD just needs more
CBD. In fact, the opposite may be true because a constant dose of CBD may dull the receptors by interfering with upregulating. Once again,
tailoring the treatment for the patient.
Dr. Pai’s presentation is highly recommended and available for viewing at: https://cemoodle.nunm.edu/course/category.php?id=221
Cannabis in Cancer Care
Presenter: Neil McKinney, BSc, ND
Vital Victoria Naturopathic Clinic
Neil McKinney is a practicing naturopath from Canada who
specializes in treating cancer patients. He has been a clinician for
nearly forty years and his presentation was a delightful mix of
pertinent information along with some homespun common sense.
His comments in the first two minutes of the presentation set the
stage for what was to come when he expressed his fascination with the
ECS and declared how delighted he was to have natural cannabinoid
products available for his patients because “it is part of our biological
heritage, it’s part of our legal right to have this plant.”
He quickly ran through the main cannabinoids — THC, CBD, CBC,
CBN and CBG — making it clear that he is a great fan of aggressive
research into the many cannabinoids but rather confidently predicted
that CBG (cannabigerol) will “be the next big bomb.” He has used
CBG together with CBD and THC to treat cancers with some success.
One of the most informative sections of his talk had to do with
concerns about using cannabis to treat children and he listed the
reasons why.
Dr. McKinney provided a comprehensive look at his philosophy
relative to treating cancer patients with cannabis. He basically
addressed two separate areas. First, he dispelled the concerns relative
to using a natural medicine like cannabis with today’s sophisticated
oncology medications. Acknowledging the number of clinicians in the
audience he stated categorically,
“There are very, very few interactions between natural medicines
and oncology drugs. Period. End of story. Forty years of
experience in the field and I tell you you really don’t have to
sweat it that much.”
Secondly, he addressed the use of cannabis, in particular pure THC
oil, for treatment of cancer, cautioning the clinicians that the high
doses required to make the THC effective can really create adverse
effects in patients. He advocates administering citicoline or CBD
prior to dosing with THC oil saying it will help mitigate the effects
of THC. (Note: some practitioners feel citicoline can be harmful for
cancer patients, especially those with brain tumors.)
Dr. McKinney provided several case studies from his practice as well
as those found in the literature. Space will not allow recounting these
several cases. For those seeking specific information on this topic the
complete talk with powerpoint slides is available at:
http://www.nunm.edu/ceonline
6

Cannabinoids and Opiates: Crosstalk and Connections with Regard to
Reward, Addiction, Dependence and Recovery
Presenter: Kevin Wilson, ND, DAAPM
Kevin Wilson, ND had the unenviable position of final speaker at a
two-day conference. The good doctor never acknowledged it but it
seemed to this writer that he was exhibiting some of the same feelings
as those in the audience. He seemed weary and a bit dazed by the
wealth of information that had come before him. At one point he said
that what he had learned that week-end was a little “overwhelming.”
The room seemed to issue a collective thought of, “Amen!”
Nevertheless Dr. Wilson had come to present on Cannabinoids and
Opioids so he pressed on with his slides in an almost apologetic
fashion. Claiming to be “pro cannabis” he noted that he was beginning
to have “reservations because [cannabis] does lead to dependency”
and later noting that perhaps “we need to put it back in perspective
after this sort of post prohibition time.” Dr. Wilson spoke with the
air of someone wanting to stop the hands of time. It was a peculiar
presentation in that regard.
As the talk proceeded it seemed apparent that what puzzled Dr.
Wilson was what Dr. Pai had addressed in his talk: the complexity of
the cannabis plant and the realization that cannabinoid receptors are
far more complex than “on or off.” For Dr. Wilson, like Dr. Bergner
on the first day, there was almost and annoyance that cannabis was
proving so difficult to fathom.
Award-Winning Transdermal Patch Patch
He noted that in states that have legalized cannabis for medical
purposes there is a drop in prescription pain medications and tipped
his hat to the work of Ashley and W. David Bradford which has shown
significant economic savings in those states.
Dr. Wilson’s confusion is fueled, in part, by his compassion. He
wants to help opioid addicts and those in pain. He views cannabis
as a possible tool in that quest. His admitted a fascination with
neural plasticity (“the love of my [academic] life”) and the vast
complexity of the human brain. As a practitioner he seems frustrated,
almost conflicted, with the unexpected complexity of cannabis,
particularly with respect to dosing. This is a common problem, not
just for naturopaths but also MDs who are recommending cannabis.
Naturopaths, however, seem almost guilty about this internal conflict,
perhaps because cannabis is a natural product.
As Dr. Wilson made his way through his presentation he provided
leads to some excellent research articles. Several of them are listed on
page 8. He made his case for cannabis addiction (which should have
been called THC addiction) by citing several studies (all animal based)
and concluded that approximately 7% of cannabis users are estimated
to become addicted. But then he added, “I’m beginning to realize that
people can be addicted to all kinds of things.”
The final third of his presentation gave attendees some ideas relative
to treating withdrawal with a variety of available pharmaceuticals
including clonidine, Immodium and even ketamine.
It is ironic that the naturopathic conference on medical cannabis
would begin and end with presentations so heavily weighted in the
issue of alcohol and opioid addiction and treatment. Perhaps this
investiture in the recovery community has made it particularly difficult
for NDs to embrace medical cannabis. Certainly this conference
revealed hints of that.
The The Remedy Tincture
• Quick • Quick onset onset & unsurpassed & unsurpassed duration duration
• Discreet • Discreet & easy & to easy use to for use all for day all (or day night) (or night) relief relief
• Adheres • Adheres simply simply to any to veinous any veinous part of part the of skin the skin
www.MarysMedicinals.com
• Mary’s best-selling sublingual tincture packed with 500mg of organic CBD
• Has potential to provide an array of benefi ts including pain relief, antiinflammatory,
anxiety reducer, antispasmodic and more
• Intended for proactive daily cannabinoid therapy
• One of the most concentrated and pure full-spectrum tinctures
on the market
www.MarysMedicinals.com
7

Bibliographies
The following references are from the presentations of several speakers at the National University of
Naturopathic Medicine (NUNM) Medical Cannabis Conference. The citations are, for the most part,
available online, particularly using Google Scholar.
Dr. Kevin Spelman: CBD and Terpenes
Cannabidiol Enhances the Inhibitory Effects of delta-9-Tetrahydrocannabinol
Cannabidiol on Human Glioblastoma Enhances the Cell Inhibitory Proliferation Effects and of delta-9-Tetrahydrocannabinol
Survival, Marcu, et al.,
on Human Glioblastoma Cell Proliferation and Survival, Marcu, et al.,
Even High Doses of Oral Cannabidol Do Not Cause THC-Like Effects in
Molecular Cancer Therapy. 2010; 180-189. https://www.ncbi.nlm.nih.gov/
Molecular Cancer Therapy. 2010; 180-189. https://www.ncbi.nlm.nih.gov/
Humans: Comment on Merrick et al. F. Grotenhermen Franjo, Russo Ethan,
pubmed/20053780
pubmed/20053780
and Zuardi Antonio Waldo. Cannabis and Cannabinoid Research. January 2017,
2(1): 1-4. https://doi.org/10.1089/can.2016.0036
The Path Ahead - What Should We Tell Our Patients about Marijuana
The (Cannabis Path Ahead indica - and What Cannabis Should We sativa)? Tell Our Pizzorno, Patients Integrative about Marijuana Medicine. 2016;
(Cannabis indica and Cannabis sativa)? Pizzorno, Integrative Medicine. 2016;
Cannabidiol in Inflammatory Bowel Diseases: A Brief Overview. G. Esposito,
15 (6): 8-12. https://www.ncbi.nlm.nih.gov/pubmed/28223891
15 (6): 8-12. https://www.ncbi.nlm.nih.gov/pubmed/28223891
et. al. Phytotherapy Research, May 2013, 27(5): 633-636. https://www.ncbi.
nlm.nih.gov/pubmed/22815234
Cannabis Extract Treatment for Terminal Acute Lymphoblastic Leukemia with
Cannabis a Philadelphia Extract Chromosome Treatment for Mutation, Terminal Singh Acute & Lymphoblastic Bali, Case Reports Leukemia in Oncology with
a Philadelphia Chromosome Mutation, Singh & Bali, Case Reports in Oncology
Neuroprotective Antioxidants from Marijuana. A.J. Hampson, et. al., Annals
2013; 6: 585-592. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901602/
2013; 6: 585-592. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901602/
of the New York Academy of Sciences, January 2000, Vol 899. https://www.ncbi.
nlm.nih.gov/pubmed/10863546
Dr. Kevin Wilson: Cannabis and
Dr. Kevin Wilson: Cannabis and
Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of Opioid Withdrawal
pediatric epilepsy: A potential role for infantile spasms and Lennox–Gastaut
Opioid Withdrawal
syndrome. S.A. Hussain, et.al., Epilepsy & Behavior, June 2015. Vol 47, pos. Medical Cannabis Use Is Associated With Decreased Opiate Medication Use
138-141. https://www.ncbi.nlm.nih.gov/pubmed/25935511
Medical in a Retrospective Cannabis Cross-Sectional Use Is Associated Survey With of Decreased Patients With Opiate Chronic Medication Pain. Use K. F.
in Boehnke, a Retrospective E. Litinas, Cross-Sectional and D.J. Clauw, Survey The of Journal Patients of Pain, With Volume Chronic 17, Pain. Issue K. 6, F.
Handbook of Cannabis Therapeutics: From Bench to Bedside, E. Russo and F.
Boehnke, June 2016, E. pages Litinas, 739-744. and D.J. https://www.ncbi.nlm.nih.gov/pubmed/27001005
Clauw, The Journal of Pain, Volume 17, Issue 6,
Grotenhermen, Routledge, 2006.
June 2016, pages 739-744. https://www.ncbi.nlm.nih.gov/pubmed/27001005
Substitution of medical cannabis for pharmaceutical agents for pain,
Substitution anxiety, and sleep. of medical B.J. Piper, cannabis R.M. for DeKeuster, pharmaceutical M.L. agents Beals, for et.al. pain, Journal of
anxiety, and sleep. B.J. Piper, R.M. DeKeuster, M.L. Beals, et.al. Journal of
Dr. Neil McKinney: Cannabis In Cancer Care Psychopharmacology, Volume 31, Issue 5, April 4, 2017. http://bit.ly/2n3BPWb
Psychopharmacology, Volume 31, Issue 5, April 4, 2017. http://bit.ly/2n3BPWb
Integrating cannabis into clinical cancer care, Curr. Oncology. Abrams, D., Cannabis and intractable chronic pain: an explorative retrospective analysis of
Cannabis and intractable chronic pain: an explorative retrospective analysis of
2016 ; 23 (2): S8-S14. https://www.ncbi.nlm.nih.gov/pubmed/27022315 Italian cohort of 614 patients. G. Fanelli, et. al., Journal of Pain Research, 2017;
Italian 10: pages cohort 1217-1224. of 614 patients. https://www.ncbi.nlm.nih.gov/pubmed/28579820
G. Fanelli, et. al., Journal of Pain Research, 2017;
10: pages 1217-1224. https://www.ncbi.nlm.nih.gov/pubmed/28579820
Cannabis Use and Risk of Lung Cancer: A Case Control Study, European
Respir. J., Aldington, Harwood, Cox, et al., 2008; 31 (2): 280-286. https:// Opioid withdrawal suppression efficacy of oral dronabinol in opioid
Opioid withdrawal suppression efficacy of oral dronabinol in opioid
www.ncbi.nlm.nih.gov/pubmed/18238947
dependent humans. M.R. Lofwall et. al., Drug and Alcohol Dependence,
dependent Volume 164, humans. July 2016, M.R. pages Lofwall 143-150. et. al., https://www.ncbi.nlm.nih.gov/
Drug and Alcohol Dependence,
Volume 164, July 2016, pages 143-150. https://www.ncbi.nlm.nih.gov/
Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in pubmed/27234658
pubmed/27234658
cancer patients: results of a randomized, double-blind, placebo-controlled pilot
trial, Annals of Oncology, Brisbois, de Kock, Watanabe, et al., 2011; 22 (9): Cannabinoid and opioid interactions: Implications for opiate dependence and
Cannabinoid and opioid interactions: Implications for opiate dependence and
2086-2093. https://www.ncbi.nlm.nih.gov/pubmed/21343383.
withdrawal, J.L. Scavone, R.C. Sterling, E.J. Van Bockstaele. Neuroscience,
withdrawal, Volume 248, J.L. September Scavone, 2013, R.C. Sterling, pages 637-65. E.J. Van https://www.ncbi.nlm.nih.gov/
Bockstaele. Neuroscience,
Volume 248, September 2013, pages 637-65. https://www.ncbi.nlm.nih.gov/
Cannabinoids: A new hope for breast cancer therapy?, Cancer Treatment. pubmed/23624062
pubmed/23624062
Caffarel, Andradas, Pérez-Gómez, et al.,Rev. 2012; 38 (7): 911–918. https://
www.ncbi.nlm.nih.gov/pubmed/22776349
Patented Transdermal Gel Pen
Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic
reticulum stress-related genes. Carracedo, Gironella, Lorente, et al.
Cancer Research. 2006; 66: 6748–55. https://www.ncbi.nlm.nih.gov/
pubmed/16818650.
Medical marijuana: the conflict between scientific evidence and political
ideology. Part two of two. Cohen, P.J. J Pain Palliat Care Pharmacotherapy.
2009;23:120-140. https://www.ncbi.nlm.nih.gov/pubmed/19296351
Comparison of the analgesic effects of dronabinol and smoked marijuana in
daily marijuana smokers. Cooper, Comer & Haney. Neuropsychopharmacology.
2013 Apr 22. https://www.ncbi.nlm.nih.gov/pubmed/23609132
Marijuana Smoking in Patients With Leukemia, Khwaja; Yacoub, Cheema,
et al., Cancer Control 2016; 23 (3):278-283. https://www.ncbi.nlm.nih.gov/
pubmed/27556668
Adverse Structural and Functional Effects of Marijuana on the Brain: Evidence
Reviewed. Mandelbaum & de la Monte, Pediatric Neurology. 2017; 66: 12-20.
https://www.ncbi.nlm.nih.gov/pubmed/27789118
• Accurately dosed, personalized cannabinoid blend
• Fast acting, high bioavailability, premium quality
• Rapid pain relief
www.MarysMedicinals.com
8